Sam Smith (@scolbysmith)
Activity by Sam Smith
ROCHESTER, Minn. — A. Keith Stewart, M.B., Ch.B., has been appointed medical director of the Mayo Clinic Center for Individualized Medicine. Dr. Stewart is a consultant in the Division of Hematology-Oncology, Department of Medicine.
“I am honored to have this opportunity,” says Dr. Stewart. “We will build on the excellent work of the center to date, with a renewed focus on helping our clinicians access genomics based diagnostics and therapeutics on a routine basis to improve patient care. The integrated complex care delivered at Mayo Clinic provides a unique ability to lead in the development of precision medicine advances with global impact.”
Dr. Stewart’s own research and clinical interest is in translational genomics in multiple myeloma, including both basic and clinical research to identify novel targets for therapy in multiple myeloma. A diversity of public and private institutions currently support this work: the National Cancer Institute, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society, as well as numerous partnerships with the pharmaceutical industry for clinical trials. [...]
ROCHESTER, Minn. — Sen. Amy Klobuchar (D-Minn.) affirmed her commitment to medical innovation and precision medicine today during a tour of the Mayo Clinic Biorepositories' new state-of-the-art space in northwest Rochester.
"President Obama made precision medicine a common term ... and I'm delighted to be here to see first-hand the work that has been going here at Mayo Clinic for quite some time," Klobuchar said. "We need to continue to support medical research and fund the NIH—we increasingly are facing international competition."
Obama announced the NIH's $270 million Precision Medicine Initiative on January 20 during this year's State of the Union Address, thrusting the relatively obscure medical term into the national spotlight and launching a national dialogue about medical innovation and genomics in clinical care.
Klobuchar called the initiative "imperative" to the future of health care in the United States and a key component of the local and state economies.
"America has always been a leader (in health innovation)," Klobuchar said. "We want those dollars, those jobs, right here in Rochester, in the Twin Cities." [...]
ROCHESTER, Minn. — Sen. Amy Klobuchar, D-Minn., will tour the Mayo Clinic Biobank and discuss the Precision Medicine Initiative with leadership from both the Mayo Clinic Center for Individualized Medicine and Mayo Medical Laboratories. Journalists are welcome to accompany Sen. Klobuchar and join the informational tour of Mayo Clinic’s multi-million-dollar investment in precision medicine. Mayo Clinic leadership will also be available for interviews and background discussions.
WHAT: Walking tour of the Mayo Clinic Biobank and the Biorepositories Program of the Mayo Clinic Center for Individualized Medicine. Photo opportunities and opportunities to discuss the Precision Medicine Initiative with Sen. Klobuchar and Mayo Clinic leadership.
WHERE: Biorepositories Building of Mayo Clinic, 2915 Valleyhigh Drive NW, Rochester, MN 55901. Entrance is behind the building.
WHEN: Friday, February 20, from 11:15 to 11:40 a.m.
NOTE: Members of the media should RSVP to 507-284-5005.
MEDIA CONTACT: Sam Smith, 507-284-5005, firstname.lastname@example.org.
Mayo Clinic is excited about the national focus on individualized medicine and what the future holds. More than half ($130 million) of the total $215 million budget request, put forth by President Obama's Precision Medicine Initiative, is for a national biobanking initiative that draws on existing collections across the country. Mayo Clinic has among the country’s largest collections through the Mayo Clinic Biobank and the Biorepositories Program.
Mayo Clinic and the Mayo Clinic Center for Individualized Medicine have made a significant commitment to building a scalable biorepository infrastructure, which includes multiple specimen processing laboratories and centralized storage.
One of these collections is the Mayo Clinic Biobank, a collection of blood samples and health information donated by Mayo Clinic patients. The Biobank collects samples and health information from patients and other volunteers, regardless of health history. The Biobank was established at Mayo Clinic's campus in Rochester, Minn., and recruitment began in April 2009. Since then, the Biobank has expanded to Mayo Clinic's campuses in Jacksonville, Fla. and Scottsdale, Ariz., in addition to the Mayo Clinic Health System. The Biobank aims to enroll 50,000 Mayo Clinic patients by 2016 to support a wide array of health-related research studies at Mayo Clinic and other institutions.
Steve Thibodeau, David F. and Margaret T. Grohne Director, Biorepositories Program facts about the Mayo Clinic Biobank.
Journalists: Soundbites with Dr. Thibodeau and b-roll of the Mayo Clinic Biobank are available in the downloads.
MEDIA CONTACT: Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, email@example.com
Rochester, Minn. — A new breast imaging technique pioneered at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study published this week in the American Journal of Roentgenology.
Molecular Breast Imaging (MBI) is a supplemental imaging technology designed to find tumors that would otherwise be obscured by surrounding dense breast tissue on a mammogram. Tumors and dense breast tissue can both appear white on a mammogram, making tumors indistinguishable from background tissue in women with dense breasts. About half of all screening-aged women have dense breast tissue, according to Deborah Rhodes, M.D., a Mayo Clinic Breast Clinic physician and the senior author of this study.
MBI increased the detection rate of invasive breast cancers by more than 360 percent when used in addition to regular screening mammography, according to the study. MBI uses small, semiconductor-based gamma cameras to image the breast following injection of a radiotracer that tumors absorb avidly. Unlike conventional breast imaging techniques, such as mammography and ultrasound, MBI exploits the different behavior of tumors relative to background tissue, producing a functional image of the breast that can detect tumors not seen on mammography.
The study, conducted at Mayo Clinic, included 1,585 women with heterogeneously or extremely dense breasts who underwent an MBI exam at the time of their screening mammogram.
Individualized medicine, also known as personalized medicine or precision medicine, means tailoring diagnosis and treatment to each patient to optimize care. Patients have experienced this kind of care for 150 years at Mayo Clinic, where teams of specialists have always worked together to find answers.
Now, at a time when we can routinely sequence a whole human genome and better understand the function of genes, individualized medicine at Mayo Clinic has been taken to the molecular level. We're using genomics and other sequencing technologies to more effectively and precisely diagnose, treat, predict and eventually prevent disease.
And that's what the Center for Individualized Medicine is all about — solving the clinical challenges of today and tomorrow by bringing the latest discoveries from the research laboratory to your doctor's fingertips in the form of new genomics-based tests and treatments.
MEDIA CONTACT: Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org [...]
ROCHESTER, Minn. — Before reaching for that daily antacid, you might consider what it’s doing to the trillions of bugs living in your gut. A new Mayo Clinic study in the open access journal Microbiome shows that people who regularly take proton pump inhibitors (PPIs) have less diversity among their gut bacteria, putting them at increased risk for infections like clostridium difficile and pneumonia, in addition to vitamin deficiencies and bone fractures.
MEDIA CONTACT: Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, Email: email@example.com
Journalists: Soundbites with Dr. DiBaise are available in the downloads. [...]
ROCHESTER, Minn. — A diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung, a Mayo Clinic study has found. For patients with multiple tumors, that distinction could mean the difference between early stage cancer that may be cured by surgery and incurable late-stage disease. The research is published this week in the Journal of Clinical Oncology.
“Unfortunately, distinguishing between independent primary tumors and metastasis is a frequent dilemma for pathologists” says Marie-Christine Aubry, M.D., a Mayo Clinic pathologist and co-principal author of the study. “We need better tests to help the clinician match the treatment approach to the patient’s individual needs.”
Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org
Journalists: Soundbites with Dr. Wigle are in the downloads. [...]